Three EU authorities combine forces to assess blood glucose products: results
This article was originally published in Clinica
Executive Summary
It has long been argued that resources could be saved in the overseeing of the EU medical devices market through competent authorities working more closely together. This is starting to happen with increasing frequency and results from a co-ordinated post-market surveillance operation between three regulatory authorities demonstrate how increased co-operation can give a broader and even more useful overview of what is happening in the market.